Aurobindo Pharma Announces 39th AGM on Aug 27, 2026, and E-voting Details
Aurobindo Pharma Limited will hold its 39th AGM on August 27, 2026, via VC/OAVM. E-voting is scheduled from August 24-26, 2026, with a cut-off date of August 20, 2026. The Integrated Annual Report for FY25-26 is available online.
This is a standard regulatory filing related to the annual general meeting and report dissemination, which is a routine corporate event and has minimal direct impact on the company's operations or stock price.
The announcement is a routine corporate communication regarding the AGM and availability of the annual report, with no significant financial or business updates that would indicate a positive or negative sentiment.
Aurobindo Pharma Limited has announced that its 39th Annual General Meeting (AGM) will be held on Thursday, August 27, 2026, at 3:30 p.m. IST. The meeting will be conducted through Video Conferencing (VC) / Other Audio-Visual Means (OAVM).
In accordance with SEBI Listing Regulations, the 39th AGM Notice and the Integrated Annual Report for the financial year 2025-26 have been emailed to shareholders who have registered their email addresses. For shareholders whose email addresses are not registered, the company has provided a web-link to access these documents on its website. The web-link is https://www.aurobindo.com/investors/disclosures-under-regulation-46/financial-information/annual-reports.
The company also provided details for e-voting. The cut-off date to determine entitlement for e-voting is Thursday, August 20, 2026. E-voting will commence on Monday, August 24, 2026, at 9:00 a.m. IST, and conclude on Wednesday, August 26, 2026, at 5:00 p.m. IST.
Shareholders are reminded to update their PAN, KYC details, and nomination details with their respective Depository Participant/RTA to ensure smooth processing of any future payments, including dividends. A dedicated 'Senior Citizens Investor Cell' has also been established by the RTA to assist senior shareholders.
What to do with a filing like this
Aurobindo Pharma Limited filed this with the NSE as a statutory disclosure, categorised under agm. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Aurobindo Pharma Limited. Read the original for the full detail.